The Controversy Surrounding Hemoglobin and Erythropoiesis-Stimulating Agents: What Should We Do Now?

American Journal of Kidney Diseases

Volumn 52, Issue 6 SUPPL. 1, 2008, Pages

  Singh, Ajay K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

anemia of chronic kidney disease; erythropoiesis stimulating agent; hemodialysis; hemoglobin levels; Intravenous iron

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG EXPOSURE; DRUG INDICATION; DRUG RESPONSE; HEART FAILURE; HEMATOCRIT; HUMAN; MORTALITY; REVIEW; STROKE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MEDICAID; MEDICARE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 55749085794     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.09.010     Document Type: Review

References (37)

1. Revicki D.A., Brown R.E., Feeny D.H., et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25 (1995) 548-554
2. Evans R.W., Rader B., and Manninen D.L. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 263 (1990) 825-830
3. Beusterien K.M., Nissenson A.R., Port F.K., Kelly M., Steinwald B., and Ware Jr. J.E. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 7 (1996) 763-773
4. Collins A.J., Li S., St Peter W., et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12 (2001) 2465-2473
5. Collins A.J., Ma J.Z., and Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 20 (2000) 345-349
6. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006) 1181-1191
7. National Kidney Foundation. DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kidney Dis 30 suppl 3 (1997) S192-S240
8. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37 suppl 1 (2001) S182-S238
9. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Adults. Am J Kidney Dis 47 suppl 3 (2006) S16-S85
10. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of hemoglobin target. Am J Kidney Dis 50 (2007) 471-530
11. US Renal Data System. USRDS 2006 Annual Data Report (2006), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
12. Coladonato J.A., Frankenfield D.L., Reddan D.N., et al. Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 13 (2002) 1288-1295
13. US Government Accountability Office. Report to the Chairman, Committee on Ways and Means, House of Representatives. End-stage Renal Disease: Bundling Medicare′s Payment for Drugs With Payments for All ESRD Services Would Promote Efficiency and Clinical Flexibility (2006), GAO 07-77, Washington, DC
14. Cotter D., Thamer M., Narasimhan K., Zhang Y., and Bullock K. Translating epoetin research into practice: The role of government and the use of scientific evidence. Health Aff (Millwood) 25 (2006) 1249-1259
15. Thamer M., Zhang Y., Kaufman J., et al. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297 (2007) 1667-1674
16. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
17. Singh A.K., Szczech L., Tang K.L., and CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
18. Drüeke T.B., Locatelli F., Clyne N., and CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
19. US Food and Drug Administration Advisory Committee. : Briefing Document, Joint Meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee. FDA, September 11, 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-01-FDA.pdf Accessed March 3, 2008
20. Besarab A., Goodkin D.A., Nissenson A.R., and Normal Hematocrit Cardiac Trial Authors. The Normal Hematocrit Study-Follow-up. N Engl J Med 358 (2008) 433-434
21. Wolf R.F., Gilmore L.S., Friese P., Downs T., Burstein S.A., and Dale G.L. Erythropoietin potentiates thrombus development in a canine arterio-venous shunt model. Thromb Haemost 77 (1997) 1020-1024 (abstr)
22. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006) 1181-1191
23. Zhang Y., Thamer M., Stefanik K., et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44 (2004) 866-876
24. US Food and Drug Administration and Center for Drug Evaluation and Research. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA). http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm Accessed February 25, 2008
25. US Food and Drug Administration and Center for Drug Evaluation and Research. Questions and Answers for Erythropoiesis-Stimulating Agents (ESAs) Labeling Changes. http://www.fda.gov/CDER/drug/infopage/RHE/qa2007.htm Accessed February 25, 2008
26. Oncologic Drugs Advisory Committee. FDA Briefing Document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-01-FDA.pdf Accessed June 29, 2008
27. FDA. Aranesp (darbepoetin alfa) for injection: Prescribing information (March 2008), US Food and Drug Administration, Silver Spring, MD
28. FDA. Procrit (Epoetin alfa) for injection: Prescribing information (March 2008), US Food and Drug Administration, Silver Spring, MD
29. Centers for Medicare & Medicaid Services. CMS Manual System. Pub 100-04 Medicare Claims Processing. Transmittal 1307. Change Request 5700. 7-20-2007. http://www.cms.hhs.gov/Transmittals/Downloads/R1307CP.pdf Accessed January 3, 2008
30. Keithi-Reddy S.R., Addabbo F., Patel T.V., Mittal B.V., Goligorsky M.S., and Singh T.A.K.V. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int 74 (2008) 782-790
31. Kilpatrick R.D., Critchlow C.W., Fishbane S., et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3 (2008) 1077-1083
32. Szczech L.A., Barnhart H., Inrig J.K., et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74 (2008) 791-798
33. Coyne D.W., Kapoian T., Suki W., and DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
34. Kapoian T., O'Mara N.B., Singh A.K., et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19 (2008) 372-379
35. Taylor J.E., Peat N., Porter C., and Morgan A.G. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11 (1996) 1079-1083
36. Sepandj F., Jindal K., West M., and Hirsch D. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11 (1996) 319-322
37. Fishbane S., Frei G.L., and Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26 (1995) 41-46